Loading…
Haemonetics Corporation is projected to rise to $89.63 by 2027, a +33% move from its current price of $67.16. HAE is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $65.52 | $67.22 | $68.97 | +0.09% |
| May 30 | $64.89 | $67.29 | $69.77 | +0.19% |
| May 31 | $64.42 | $67.35 | $70.40 | +0.28% |
| Jun 1 | $64.04 | $67.41 | $70.96 | +0.37% |
| Jun 2 | $63.72 | $67.47 | $71.45 | +0.47% |
| Jun 3 | $63.43 | $67.54 | $71.91 | +0.56% |
| Jun 4 | $63.17 | $67.60 | $72.34 | +0.65% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $63.17 | $67.60 | $72.34 | +0.65% |
| Week 2 | $61.82 | $68.04 | $74.89 | +1.31% |
| Week 3 | $60.90 | $68.48 | $77.02 | +1.97% |
| Week 4 | $60.19 | $68.93 | $78.94 | +2.64% |
| Week 5 | $59.62 | $69.38 | $80.74 | +3.31% |
| Week 6 | $59.15 | $69.84 | $82.45 | +3.98% |
| Week 7 | $58.75 | $70.29 | $84.10 | +4.66% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Haemonetics Corporation is a medical technology company that provides a suite of hospital technologies solutions. The company operates through Plasma, Blood Center, and Hospital segments. It offers automated plasma collection systems, donor management software, and related disposables and solutions, including NexSys PCS plasmapheresis equipment system and NexLynk DMS donor management system with Donor360 tools.
It also supplies SavvyWire and OptoWire for advanced procedures, and a range of hospital products such as the TEG 6s system with TEG Manager software, as well as Cell Saver Elite + and VASCADE products, plus transfusion management solutions. Haemonetics was founded in 1971 and is headquartered in Boston, Massachusetts. It sells its products through direct sales force and independent distributors.
Haemonetics Corporation (HAE) is a healthcare technology stock with a current price of $65.49 and a market capitalization of $2.98B, ranking 1730. The stock sits near its shorter- and longer-term moving averages, with a 50-day simple moving average of $58.20 and a 200-day simple moving average of $62.19. The near-term outlook is supported by a bullish technical stance with a 30-day trading range of $54.84 to $78.21.
Looking ahead, the year-by-year forecast envisions sustained upside, with the average price rising from the mid-2020s toward multiple years beyond, culminating in a much higher long-term level. Forecasters project the average price to move from $65.49 in 2026 to $101.11 in 2030 and to $400.00 by 2050, reflecting meaningful long-term upside amid bullish sentiment across successive years.
A major floor 29.6% below — a decisive break under it would weaken the trend.
The nearest floor, 22.2% below — buyers have tended to step in here.
Price is pressing into resistance (0.0% away) — a breakout level to watch.
A major ceiling 14.8% above — clearing it would confirm fresh momentum.
Key HAE support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of HAE market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $64.20 | Buy | $64.43 | Buy |
| MA 10 | $60.55 | Buy | $61.81 | Buy |
| MA 20 | $58.16 | Buy | $59.92 | Buy |
| MA 50 | $58.49 | Buy | $59.78 | Buy |
| MA 100 | $62.68 | Buy | $61.58 | Buy |
| MA 200 | $62.31 | Buy | $63.71 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 69.81 | Neutral |
| Stoch RSI (14) | 100.00 | Sell |
| CCI (20) | 176.16 | Buy |
| Williams %R (14) | 0.00 | Info |
| MACD (12,26,9) | 1.42 | Buy |
| ROC (12) | 21.84 | Buy |
| Bollinger %B (20,2) | 1.03 | Sell |
| Stochastic %K (14) | 100.00 | Sell |
| TRIX (15) | 0.02 | Buy |
| Awesome (5,34) | 5.23 | Buy |
| Ultimate (7,14,28) | 86.84 | Sell |
| Momentum (10) | 13.15 | Buy |
| Aroon Osc (25) | 44.00 | Buy |
| Hull MA (9) | 68.14 | Sell |
| ADX (14) | 18.40 | Neutral |
| ATR (14) | 1.48 | Info |
The 30-day technical picture is bullish, with RSI(14) at 70 indicating strong upside momentum. The stock trades above the shorter moving average trend while showing an established up-move potential as it approaches resistance near the current price. The 50-day SMA is $58.20 and the 200-day SMA is $62.19, highlighting a constructive trend.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $52.24 | $67.16 | $97.75 | 0% | Neutral | |
| $71.51 | $89.63 | $118.76 | +33% | Bullish | |
| $75.51 | $97.07 | $133.03 | +45% | Bullish | |
| $80.38 | $105.53 | $148.56 | +57% | Bullish | |
| $80.35 | $107.50 | $154.80 | +60% | Bullish | |
| $82.64 | $112.46 | $165.20 | +67% | Bullish | |
| $89.16 | $123.29 | $184.37 | +84% | Bullish | |
| $102.49 | $143.84 | $218.63 | +114% | Bullish | |
| $119.59 | $170.25 | $262.68 | +153% | Bullish | |
| $119.90 | $173.01 | $270.69 | +158% | Bullish | |
| $160.66 | $246.53 | $409.00 | +267% | Bullish | |
| $270.12 | $460.47 | $832.41 | +586% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $52.24 | $67.16 | $78.88 | +0.00% |
| June 2026 | $59.51 | $69.79 | $83.73 | +3.92% |
| July 2026 | $61.84 | $73.11 | $88.82 | +4.75% |
| August 2026 | $61.97 | $73.70 | $90.42 | +0.82% |
| September 2026 | $62.62 | $74.86 | $92.58 | +1.57% |
| October 2026 | $65.09 | $78.18 | $97.38 | +4.44% |
| November 2026 | $65.60 | $79.12 | $99.17 | +1.20% |
| December 2026 | $64.03 | $77.53 | $97.75 | -2.02% |
Click any year to see its month-by-month HAE forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect HAE to range from $52.24 to $97.75 through 2026. The $67.16 average target implies a 0% move from current prices. A consolidation phase looks the most probable path here.
The HAE price prediction for 2027 points to an average of $89.63 (low $71.51, high $118.76) — a potential gain of +33% on today's $67.16. Momentum favours further upside here.
In 2028, HAE is projected to trade between $75.51 and $133.03, averaging $97.07 — a potential gain of +45% from today's $67.16. That is up +8% on the projected 2027 average. Buyers look set to stay in control over this stretch.
Haemonetics Corporation's 2029 outlook centres on $105.53, within a $80.38 to $148.56 range. That is up +9% on the projected 2028 average. That marks a +57% change versus current levels. Momentum favours further upside here.
By 2030, HAE could reach as high as $154.80, with a base case around $107.50 and support toward $80.35 — roughly +60% from $67.16. Buyers look set to stay in control over this stretch.
Expect HAE to range from $82.64 to $165.20 through 2031. The $112.46 average target implies a +67% move from current prices. That is up +5% on the projected 2030 average. Momentum favours further upside here.
The HAE price prediction for 2032 points to an average of $123.29 (low $89.16, high $184.37) — a potential gain of +84% on today's $67.16. Buyers look set to stay in control over this stretch.
In 2033, HAE is projected to trade between $102.49 and $218.63, averaging $143.84 — a potential gain of +114% from today's $67.16. That is up +17% on the projected 2032 average. Momentum favours further upside here.
Haemonetics Corporation's 2034 outlook centres on $170.25, within a $119.59 to $262.68 range. That is up +18% on the projected 2033 average. That marks a +153% change versus current levels. Buyers look set to stay in control over this stretch.
By 2035, HAE could reach as high as $270.69, with a base case around $173.01 and support toward $119.90 — roughly +158% from $67.16. Momentum favours further upside here.
Expect HAE to range from $160.66 to $409.00 through 2040. The $246.53 average target implies a +267% move from current prices. That is up +42% on the projected 2035 average. Buyers look set to stay in control over this stretch.
The HAE price prediction for 2050 points to an average of $460.47 (low $270.12, high $832.41) — a potential gain of +586% on today's $67.16. Momentum favours further upside here.
Investing $1,000 in HAE today (≈ 14.889815 HAE) could be worth
$6,856.35
+$5,856.35 (+586%) by 2050 · US Dollar
Based on the average projected HAE price of $460.47 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in HAEwould be worth at today's price.
$1,000 invested in HAE on May 27, 2025 (≈ 14.708046 HAE) would be worth
$987.79
-$12.21 (-1.2%) today · 0.99× · US Dollar
Based on a HAE entry price of $67.99 vs. today's $67.16.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $59.56 | $1,127.6 | +12.8% |
| 1 month ago | $60.48 | $1,110.45 | +11.0% |
| 3 months ago | $62.24 | $1,079.05 | +7.9% |
| 6 months ago | $81.35 | $825.57 | -17.4% |
| 1 year ago | $67.99 | $987.79 | -1.2% |
| All time (5.0y) ago | $57.02 | $1,177.83 | +17.8% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our HAE forecast.
Our base-case forecast reaches $130.00 around 2033.
Implied market cap at $130.00: $5.91B
The multi-year forecast paints a strong bullish trajectory, with meaningful upside across the horizon. In 2026 the average price is projected at $65.49, and by 2030 the average climbs to $101.11 with a 54.4% ROI, while the sentiment remains bullish. By 2040 the average is forecast at $216.53, with a 230.6% ROI and continued bullish sentiment, and by 2050 the average reaches $400.00 with a 510.8% ROI, still characterized as bullish.
The sequence of rising averages across years underscores sustained long-term upside, though these are estimates and not guarantees.
Tap a question to reveal the answer.
The 2026 forecast shows a min of $52.24, an average of $65.49, and a max of $95.10, with a 0% ROI and Neutral sentiment.
From 2027 onward the forecast is Bullish, with 2027 avg $87.16 (ROI 33.1%), 2028 avg $92.82 (ROI 41.7%), and 2029 avg $99.94 (ROI 52.6%), suggesting upside while noting that these are estimates, not guarantees.
The 2030 max is $147.07, which is below $150. The 2031 max rises to $153.60, indicating it could exceed $150 starting in 2031.
The 30-day range is $54.84 to $78.21.
For 2040, the min is $138.70, the avg is $216.53, the max is $364.73, with an ROI of 230.6% and a bullish sentiment.
Haemonetics Corporation Community Discussion
0Share your Haemonetics Corporation price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.